Viewing Study NCT00089661

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 12:51 PM
Ignite Modification Date: 2026-02-20 @ 4:47 PM
Study NCT ID: NCT00089661
Status: COMPLETED
Last Update Posted: 2018-10-17
First Post: 2004-08-09
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer
Sponsor: Amgen
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
None Low Bone Mineral Density View
None Osteopenia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Breast Cancer View
None Bone loss associated with Aromatase Inhibitor therapy (AIT) for non-metastatic … View
None osteopenia View
None Low bone density View